KRAS and neoplasm: Inactivating mutation in SMAD4 does not initiate the tumour genes in PDAC but serve as secondary genetic alterations following KRAS mutation,10 which was consistent with our genomic finding that both KRAS and SMAD4 had higher mutation frequency in pancreatic body/tail cancers.